Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Biomaterials ; 197: 380-392, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30703743

RESUMO

Systemic lupus erythematosus (SLE) constitutes an autoimmune disease characterized by the breakdown of tolerance to self-antigens, sustained production of pathogenic autoantibodies, and damage to multiple organs and tissues. Nanoparticle (NP)-based therapeutics have demonstrated efficacy in attenuating the progression of SLE. However, investigations of nano-drugs that address the crucial initiating factor in the pathogenesis of SLE; e.g., inefficient clearance of apoptotic cells by phagocytes and consequent accumulation of self-antigens, have seldom been reported. Here, an apoptotic cell-mimicking gold nanocage (AuNC)-based nano drug carrier capable of correcting the impaired clearance of apoptotic cells in SLE was rationally designed and generated by conjugating phosphatidylserine (PS) on the surface of liposome-coated AuNCs for liver X receptor (LXR) agonist T0901317 delivery. Notably, PS-lipos-AuNC@T0901317 could efficiently enhance apoptotic cell clearance by elevating the expression of Mer, one of the pivotal phagocytosis-associated receptors on macrophages, resulting in decreased production of anti-dsDNA autoantibodies, reduced inflammatory response, and alleviation of kidney damage in lupus model mice. Additionally, PS-lipos-AuNC could be tracked by photoacoustic imaging for nano drug carrier biodistribution. By addressing the crucial pathogenic factor of SLE, the NP-based delivery system in this study is envisioned to provide a promising strategy to treat this complex and challenging disease.


Assuntos
Apoptose , Sistemas de Liberação de Medicamentos , Ouro/administração & dosagem , Hidrocarbonetos Fluorados/administração & dosagem , Receptores X do Fígado/agonistas , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Nanocápsulas/administração & dosagem , Sulfonamidas/administração & dosagem , Animais , Autoanticorpos/análise , Citocinas/metabolismo , Progressão da Doença , Avaliação Pré-Clínica de Medicamentos , Feminino , Ouro/farmacocinética , Hidrocarbonetos Fluorados/uso terapêutico , Hidrocarbonetos Fluorados/toxicidade , Lipossomos/administração & dosagem , Nefrite Lúpica/tratamento farmacológico , Nefrite Lúpica/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos MRL lpr , Fosfatidilserinas , Sulfonamidas/uso terapêutico , Sulfonamidas/toxicidade , Distribuição Tecidual , c-Mer Tirosina Quinase/biossíntese , c-Mer Tirosina Quinase/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA